Organon (OGN) Other Non-Current Assets (2020 - 2025)

Organon (OGN) posted quarterly Other Non-Current Assets of $8.0 million for Q4 2025, down 93.33% on a QoQ basis from $120.0 million in Q1 2021.

Organon (OGN) Other Non-Current Assets (2020 - 2025) Analysis & Trends

Organon (OGN) has reported Other Non-Current Assets for 3 consecutive years, with $8.0 million the latest figure, recorded in Q4 2025.

In Q4 2025, Other Non-Current Assets changed N/A year-over-year to $8.0 million; the TTM figure through Dec 2025 stood at $8.0 million (changed N/A YoY), while the FY2025 annual figure was $8.0 million, changed N/A from the prior year.
Other Non-Current Assets came in at $8.0 million for Q4 2025 at Organon, down from $120.0 million in the prior quarter.
The five-year high for Other Non-Current Assets was $120.0 million in Q1 2021, with the low at $8.0 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn	7.23 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn	14.11 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn	10.54 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn	-
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn	19.81 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn	12.76 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn	4.55 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn	9.83 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-	200.00 Mn
10	Organon	3.53 Bn	2.41 Bn	783.00 Mn	-

Download Data